Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$2.83M$2.83M+85.0% vs Q1 2018 Net Income-$29.22M-$29.22MN/M vs Q1 2018 EPS Diluted-$0.30-$0.30N/M vs Q1 2018 Operating Income-$28,535,012N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$33,113,078N/M Margins · derivedOperating margin-1008.3%+1132.4 pt vs Q1 2018
Net margin-1032.5%+1082.4 pt vs Q1 2018
ended Mar 31, 2019 · filed May 9, 2019 · 39 d after period end